Form 4: Teva Pharmaceutical Director Rosemary A. Crane Reports Acquisition of Restricted Share Units

Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd, reported the acquisition of 9,632 restricted share units on June 6, 2024, which vest on June 6, 2025.

Summary

• On June 6, 2024, Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd, acquired 9,632 restricted share units.
• These restricted share units vest on June 6, 2025.
• Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, at the discretion of the Human Resources and Compensation Committee.
• The Ordinary Shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one Ordinary Share.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of shares by a director is generally viewed positively, but without additional context, the impact is moderate.

Positives

• The acquisition of restricted share units by a director may indicate confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting date of the restricted share units.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as part of executive compensation packages, aligning management interests with shareholder value.

Comparison to Industry Standards

• Comparing Teva's executive compensation structure with peers like Pfizer, Novartis, and Johnson & Johnson would provide context on whether the equity grants are in line with industry norms.
• Equity grants are a standard component of compensation packages for directors in publicly traded companies, including those in the pharmaceutical sector.
• The vesting period of one year is relatively standard for restricted share units.

Stakeholder Impact

• The acquisition of restricted share units by a director can positively influence shareholder sentiment by aligning management's interests with those of the shareholders.

Key Dates